A method for producing an EPA alkyl ester-containing composition includes: preparing a raw material oil containing an EPA alkyl ester in an amount of from 50 to 92% by mass in the total fatty acids, in which a mass ratio of a DHA alkyl ester to the EPA alkyl ester contained in the raw material oil is 3.3% by mass or less and further a ratio of trans isomers in the EPA alkyl ester contained in the raw material oil is 2% by mass or less; bringing the raw material oil into contact with an aqueous solution containing a silver salt; recovering the aqueous solution containing the silver salt brought into contact with the raw material oil; bringing the recovered aqueous solution containing the silver salt into contact with an organic solvent; and recovering the organic solvent brought into contact with the aqueous solution containing the silver salt.
Provided is a high-concentration and high-purity eicosapentaenoic acid-containing composition. A method for producing an eicosapentaenoic acid alkyl ester-containing composition, the method includes: (1) bringing a raw oil that contains an eicosapentaenoic acid alkyl ester into contact with an aqueous solution that contains a silver salt, and then collecting an aqueous layer; (2) adding an organic solvent to the aqueous layer, and then collecting an organic solvent layer; and (3) subjecting the organic solvent layer to vacuum distillation at a temperature of 180 to 188° C. and a tower top vacuum degree of 0.7 Pa or below, to recover the eicosapentaenoic acid alkyl ester from the organic solvent layer.
In order to provide a method for producing high-purity EPA, the present invention provides a method for producing an EPA alkyl ester-containing composition which contains 96 mass% or more of an EPA alkyl ester in the total fatty acid content thereof, and in which the trans isomer ratio in the EPA alkyl ester is 1.5 mass% or less. This method includes: (1) preparing a raw material oil containing 50-92 mass% of an EPA alkyl ester in the total fatty acid content thereof; (2) bringing the raw material oil and an aqueous solution including a silver salt into contact, the mass ratio of a DHA alkyl ester with respect to the EPA alkyl ester contained in the raw material oil being 3.3 mass% or less, and the trans isomer ratio in the EPA alkyl ester contained in the raw material oil being 2 mass% or less; (3) recovering the aqueous solution including a silver salt brought into contact with the raw material oil; (4) bringing the recovered aqueous solution including the silver salt into contact with an organic solvent; and (5) recovering the organic solvent brought into contact with the aqueous solution including a silver salt.
A61K 31/232 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
4.
EICOSAPENTAENOIC ACID ALKYL ESTER-CONTAINING COMPOSITION AND METHOD FOR PRODUCING SAME
The present invention provides an eicosapentaenoic acid-containing composition having high concentration and high purity. A method for producing an eicosapentaenoic acid alkyl ester-containing composition, which comprises (1) a process wherein a starting material oil containing an eicosapentaenoic acid alkyl ester is brought into contact with an aqueous solution containing a silver salt, and subsequently an aqueous layer is recovered, (2) a process wherein an organic solvent is added to the aqueous layer, and subsequently an organic solvent layer is recovered, and (3) a process wherein the organic solvent layer is subjected to vacuum distillation at a temperature of 180-188°C at a column top vacuum degree of 0.7 Pa or less, thereby recovering the eicosapentaenoic acid alkyl ester from the organic solvent layer.
Provided is a method for producing a polyunsaturated fatty acid while suppressing deterioration of a silver salt solution. A method for producing a polyunsaturated fatty acid-containing composition, the method comprising: supplying a raw material solution comprising an alkyl ester of polyunsaturated fatty acid and an aqueous solution comprising a silver salt to a flow channel mixer to contact the raw material solution with the aqueous solution; and collecting the aqueous solution comprising the silver salt which has been contacted with the raw material solution, in which the supplying the aqueous solution comprising the silver salt to the flow channel mixer and the collecting the same are performed concurrently.
To provide a cellulose pulverized product having excellent dispersibility in water, the present invention provides a method for manufacturing a cellulose pulverized product, said method including: hydrolyzing a cellulose-containing raw material; and wet-pulverizing the obtained hydrolyzate in a low-conductivity organic solvent by using a wet impact type pulverizer, thereby preparing a cellulose pulverized product.
B02C 17/00 - Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls
B02C 17/16 - Mills in which a fixed container houses stirring means tumbling the charge
7.
Method for producing polyunsaturated fatty acid-containing composition
Provided is a method for producing a polyunsaturated fatty acid while preventing deterioration of a silver salt solution. A method for producing a composition comprising a polyunsaturated fatty acid, comprising: supplying an aqueous solution comprising a silver salt into a reaction vessel to contact the aqueous solution with a raw material solution comprising an alkyl ester of the polyunsaturated fatty acid; and collecting the aqueous solution comprising the silver salt which has been contacted with the raw material solution from the reaction vessel, wherein the supply of the aqueous solution comprising the silver salt into the reaction vessel and the collection of the aqueous solution comprising the silver salt from the reaction vessel are carried out concurrently with each other.
Provided is a method for producing a highly unsaturated fatty acid while preventing degradation of a silver salt solution. A method for producing a highly unsaturated fatty acid-containing composition, said method comprising feeding a starting material solution containing a highly unsaturated fatty acid alkyl ester and an aqueous solution containing a silver salt into a flow channel mixer to thereby contact these solutions with each other, and then recovering the aqueous solution containing the silver salt which has been contacted with the starting material solution, wherein the feeding of the aqueous solution containing the silver salt into the flow channel mixer and recovery of the same are performed in parallel.
Provided is a fine-powder bran resistant to aggregation and settling. The method for producing processed bran includes a step for subjecting a bran to an acid or alkali treatment and a step for wet milling the resulting treated material to prepare a fine-powder bran dispersion.
C12P 7/64 - FatsFatty oilsEster-type waxesHigher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl groupOxidised oils or fats
11.
METHOD FOR PRODUCING HIGHLY UNSATURATED FATTY ACID-CONTAINING COMPOSITION
Provided is a method for producing a highly unsaturated fatty acid while suppressing the degradation of a silver salt solution. A method for producing a composition that contains a highly unsaturated fatty acid, wherein the method comprises: charging a silver-salt-containing aqueous solution into a reactor and causing contact to occur with a raw material solution containing an alkyl ester of a highly unsaturated fatty acid; and recovering from the reactor the aqueous solution containing the silver salt that has been brought into contact with the raw material solution. The charging of the aqueous solution containing a silver salt into the reactor and the recovering from the reactor are conducted in parallel.
The purpose of the present invention is to provide a ω3 desaturase that has high enzymatic activity even at normal temperatures. Specifically provided are: a polypeptide which is composed of an amino acid sequence having at least 80% sequence identity to an amino acid sequence indicated by SEQ ID NO: 2 and has ω3 desaturation activity against C20 fatty acids; and a gene associated therefor.
C12P 7/64 - FatsFatty oilsEster-type waxesHigher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl groupOxidised oils or fats
13.
METHOD OF PRODUCING LIPIDS WITH HIGH EICOSAPENTAENOIC ACID CONTENT
A lipid-producing microorganism is provided which can efficiently produce EPA. This mutant microorganism is obtained by introducing a foreign Δ17 desaturase gene, and one or more of a foreign Δ5 desaturase gene and a foreign Δ12 desaturase gene into a microorganism capable of producing ω9 highly unsaturated fatty acids or a microorganism having high arachidonic acid content in a fatty acid composition, and, after 10 days of culturing at 20°C or greater, the eicosapentaenoic acid content in the fatty acid composition is 20% or greater.
C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
C12P 7/64 - FatsFatty oilsEster-type waxesHigher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl groupOxidised oils or fats
14.
LIVESTOCK PRODUCTION METHOD AND LIVESTOCK-GROWTH PROMOTING METHOD
The present invention provides a livestock production method, the said method including supplying livestock with coenzyme-Q10-containing water, wherein the coenzyme-Q10-containing water contains coenzyme Q10 that is emulsified by using a hydrophilic substrate, and the hydrophilic substrate does not contain a synthetic surfactant.
The present invention provides a composition having a high content of highly unsaturated fatty acid alkyl ester. A method for producing a composition comprising a highly unsaturated fatty acid alkyl ester, the method comprising contacting a raw material comprising a highly unsaturated fatty acid alkyl ester with an aqueous solution comprising a silver salt and subsequently recovering an aqueous phase; adding an organic solvent to the aqueous phase, and subsequently recovering an organic solvent phase; and rectifying the organic solvent phase at a temperature of 170 to 190° C. and a column top vacuum degree of 1 Pa or less to recover the highly unsaturated fatty acid alkyl ester from the organic solvent phase.
Provided is an ω3 desaturase having high enzymatic activity even at normal temperature. A polypeptide comprising an amino acid sequence having 80% or higher identity with an amino acid sequence shown by SEQ ID NO: 2 and having ω3 desaturation activity, and a gene thereof.
C12P 7/64 - FatsFatty oilsEster-type waxesHigher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl groupOxidised oils or fats
A23K 1/16 - supplemented with accessory food factors; Salt blocks
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A lipid-producing microorganism capable of efficiently producing EPA is provided. A mutant microorganism obtained by introducing a foreign ∆15 desaturase gene, or a foreign ∆12 desaturase gene and one or both of a foreign ∆15 desaturase gene and a foreign ∆17 desaturase gene, into a microorganism having an ω6 polyunsaturated fatty acid metabolic pathway, the eicosapentaenoic acid content in a fatty acid composition being at least 20% after culturing of the mutant microorganism for 10 days at 20°C or higher.
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12P 7/64 - FatsFatty oilsEster-type waxesHigher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl groupOxidised oils or fats
A61K 8/36 - Carboxylic acidsSalts or anhydrides thereof
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Provided is a colon delivery system which enables the delivery of an active ingredient to the large intestine without losing the active ingredient in the stomach or the small intestine and can release the active ingredient in the large intestine rapidly. A colon delivery composition comprising a capsule that encapsulates a bacterium useful for the large intestine, alginic acid and a calcium salt therein, a chitosan-containing layer that covers the capsule, and an enteric-base-material-containing layer (i.e., a layer containing an enteric base material) that covers the chitosan-containing layer, wherein the mass of chitosan in the chitosan-containing layer is 0.5 to 8.0 mass% relative to the mass of the capsule.
The present invention provides a composition having a high higher unsaturated fatty acid content. A method for producing a composition containing a higher unsaturated fatty acid alkyl ester, wherein the method includes: bringing a raw material containing a higher unsaturated fatty acid alkyl ester into contact with an aqueous solution containing a silver salt and subsequently recovering the aqueous phase; adding an organic solvent to the aqueous phase, and subsequently recovering the organic solvent phase; and vacuum-distilling the organic solvent phase at a temperature of 170 to 190ºC and a column top vacuum degree of 1 Pa or less to recover the higher unsaturated fatty acid alkyl ester from the organic solvent.
Provided is a composition stably containing a sulfur amino acid, which is derived from an Allium plant, at a high concentration. A method for producing a sulfur amino acid-containing composition, said method comprising: a step for heating an Allium plant; a step for treating the heated Allium plant with a γ-glutamyl bond cleaving enzyme; and a step for subjecting the enzyme-treated product to ion exchange chromatography.
A23L 1/212 - Preparation of fruits or vegetables (of pulse A23L 1/20; treating harvested fruit or vegetables in bulk A23N)
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
Provided is a material which is safe and inexpensive, can be ingested easily and continuously on a daily basis, and has a significant anti-inflammatory activity. An anti-inflammatory agent comprising a mixture of: a soybean seed or an extract thereof each of which has been activated by a light irradiation treatment and/or a heating treatment; and chlorophyll.
A23L 2/00 - Non-alcoholic beveragesDry compositions or concentrates thereforPreparation or treatment thereof
A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
A61K 8/97 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from algae, fungi, lichens or plantsCosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from derivatives thereof
A61K 31/409 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
Provided is a capsule for delivering a bifidobacterium into the large intestine, said capsule comprising a hard capsule, which comprises, as a base material, gelatin or a cellulose derivative, and the bifidobacterium which is enclosed in said hard capsule, wherein a band seal is provided in the joint part of the capsule and a chitosan-containing layer and an enteric base material-containing layer are formed in this order on the surface of the capsule. Also provided is a method for producing the aforesaid capsule.
SHIZUOKA PREFECTURE PUBLIC UNIVERSITY CORPORATION (Japan)
Inventor
Isemura Mamoru
Kaneko Akihiro
Yasui Kensuke
Abstract
Disclosed is an agent which can be produced readily, is easy to ingest, and has an anti-allergic activity. An extract of green soybean with a solvent can be used as an anti-allergic agent. The extract of green soybean with a solvent has an inhibitory activity on the production of IgE and an activity of deflecting the Th1—Th2 balance in the Th1 side direction, and is therefore useful as an anti-allergic agent.
A61K 8/97 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from algae, fungi, lichens or plantsCosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from derivatives thereof
A61Q 17/00 - Barrier preparationsPreparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
It is intended to provide an antiinflammatory composition which is highly effective without any fear of side effects, can be easily taken and enables prolonged intake from the standpoints of cost and safety. Namely, a peptide comprising an amino acid represented by the formula pyroGlu-(X)n-A (wherein X's are the same or different and each represents Gln, Asn or Pro; A is Gln, Asn, Leu, Ile, Met, Val or Phe; and n is an integer of 0 to 2) or its salt, and an antiinflammatory composition containing the same.
A stable astaxanthin-containing composition which has neither an unpleasant taste nor an unpleasant odor and has a good flavor and improved solubility in aqueous liquids. Also provided is a composition having improved astaxanthin absorbability. The astaxanthin-containing water-soluble composition is characterized by comprising astaxanthin, a dextrin, and casein. Furthermore provided are: an aqueous solution obtained by dispersing the composition in an aqueous liquid; and a process for producing an aqueous solution containing astaxanthin.
It is intended to provide a composition which shows a favorable fat absorption inhibitory activity, is capable of being safely and easily taken continuously without side effects, and further is capable of preventing and/or improving conditions associated with excessive fat absorption such as obesity and hyperlipidemia. The invention relates to a fat absorption inhibiting composition containing, as an active ingredient, a component recovered as an insoluble substance by subjecting wheat germ to extraction using water at a temperature of 65˚C or lower and under an acidic condition of a pH value of 5.0 or lower, and subjecting the resulting extraction liquid to the following condition (1) and/or (2): (1) a condition of a pH value of 6.0 or higher, and (2) a condition of a temperature of 70˚C or higher.
Disclosed is a composition which can inhibit the accumulation of a fat in an adipocyte to thereby prevent the hypertrophy of the adipocyte, has no concern about adverse side effects, is highly safe, can be ingested in a simple manner, and can be ingested continuously over a long period. Specifically disclosed are: a composition for inhibiting the accumulation of a fat in an adipocyte; a composition for promoting the reduction in the size of an adipocyte; a composition for inhibiting the differentiation of an adipocyte; and a composition for preventing and/or ameliorating obesity and/or metabolic syndrome, each of which comprises at least one plant selected from a plant belonging to the family Compositae, the genus Tragopogon and a plant belonging to the family Compositae, the genus Scorzonera or an extract from the plant as an active ingredient.
A61K 8/97 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from algae, fungi, lichens or plantsCosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from derivatives thereof
A preventive or therapeutic agent for frequent urination and urinary incontinence containing as an active ingredient, a 1,4-benzodioxine derivative represented by the general formula (I): (wherein A represents an aryl group or a C3-8 cycloalkyl group, R1 and R2 are the same or different and represent a hydrogen atom, a halogen atom, a C1-6 alkyl group, a trifluoromethyl group, a C1-6 alkoxy group, an aryl group, an aryloxy group or an aryl C1-6 alkyloxy group (the aryl group, aryloxy group or aryl C1-6 alkyloxy group may be optionally substituted with one or two halogen atoms), or R1 and R2 are combined to represent -OCH2O-, R3 represents a hydrogen atom or a C1-6 alkyl group, R4 represents a hydrogen atom or CO2R5, R5 represents a hydrogen atom or a C1-6 alkyl group, X represents a divalent group having a moiety of the general formula (II) (wherein n represents 1 or 2), or (III) ) or a pharmacologically acceptable salt thereof.
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61P 13/10 - Drugs for disorders of the urinary system of the bladder
C07D 319/20 - 1,4-DioxanesHydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
[PROBLEMS] To provide: a plant growth promoter which is highly safe and is not harmful to the human body; a plant growth promoter which has an excellent plant growth promoting activity even in a wide temperature range from a lower temperature to a higher temperature; a plant growth promoter in which ubiquinone can be maintained stably, which can be dispersed uniformly and can exist stably in a soil or a medium for supplying the nutrients to a plant (e.g., an aqueous liquid), and which can be used for a plant effectively; and a plant growth promoter which is effective at any phase in the initial growth stage of a plant. [MEANS FOR SOLVING PROBLEMS] Ubiquinone is used as an active ingredient of a plant growth promoter.
A01N 35/06 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having two bonds to hetero atoms with at the most one bond to halogen, e.g. aldehyde radical containing keto or thioketo groups as part of a ring, e.g. cyclohexanone, quinoneDerivatives thereof, e.g. ketals
Disclosed is a composition for effectively preventing or treating a peptic ulcer that is not induced by Helicobacter pylori, which has no adverse side effect and is highly safe. Specifically disclosed is a composition for preventing and/or treating a peptic ulcer that is not induced by Helicobacter pylori, which comprises a browning reaction product of a sugar and a protein as an active ingredient.
A61K 31/7004 - Monosaccharides having only carbon, hydrogen and oxygen atoms
A61K 31/7016 - Disaccharides, e.g. lactose, lactulose
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A23C 9/13 - Fermented milk preparationsTreatment using microorganisms or enzymes using additives
A23G 1/00 - CocoaCocoa products, e.g. chocolateSubstitutes therefor
A23G 1/30 - Cocoa products, e.g. chocolateSubstitutes therefor
NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY (Japan)
Inventor
Sanada, Hiroo
Sato, Kenji
Ono, Shin
Suzuki, Yoshio
Abstract
It is intended to provide a composition having preventive and/or therapeutic effects on a lung disease which can be easily taken without a risk of side effects and can be administered over a long period of time from the viewpoints of cost and safety. Namely, a peptide comprising an amino acid sequence that is represented by the following formula: pyroGlu-(X)n-A (wherein X's may be either the same or different and each represents Gln or Asn; A represents Gln, Asn, Leu, Ile or Val; and n is an integer of 0 to 2) or a salt thereof.
C07K 5/072 - Dipeptides the side chain of the first amino acid containing more carboxyl groups than amino groups, or derivatives thereof, e.g. Asp, Glu, Asn
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
C07K 5/113 - Tetrapeptides the side chain of the first amino acid containing more carboxyl groups than amino groups, or derivatives thereof, e.g. Asp, Glu, Asn
32.
CAPSAICIN RECEPTOR ACTIVATOR AND APPARATUS FOR SPRAYING THE SAME
[PROBLEMS] To provide a capsaicin receptor agonist (activator) having the same various physiological activities as those of capsaicin and has no pungency, and to provide a capsaicin receptor activator which is readily available, is highly safe, shows no adverse side effect even when ingested for a long period, and has high efficacy. [MEANS FOR SOLVING PROBLEMS] Disclosed is a capsaicin receptor activator comprising, as an active ingredient, a monoacylglycerol having a saturated or unsaturated fatty acid having 2 to 22 carbon atoms as a constituent fatty acid.
A61K 31/231 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
A61K 36/53 - Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
A61K 36/896 - Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
A61K 36/899 - Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
[PROBLEMS] To provide a prophylactic and therapeutic agent for obesity which has a more effective and potent efficacy and has reduced adverse side-effects, and also provide a method for prevention and treatment of obesity. [MEANS FOR SOLVING PROBLEMS] Provided is a prophylactic or therapeutic agent for obesity, comprising a combination of a 1,4-benzodioxine derivative represented by the general formula (I) [e.g., 6-[2-(R)-[(2-(R)-(3-chlorophenyl)-2- hydroxyethyl)amino]-propyl]-2,3-dihydro-1,4-benzoxine-2- (R)-carboxylic acid] or a pharmacologically acceptable salt thereof and a cannabinoid receptor antagonist. (I)
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07D 231/14 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D 319/20 - 1,4-DioxanesHydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
[PROBLEMS] To provide an anti-hypertensive agent which requires no complicated manipulation and has an anti-hypertensive effect or a function of lowering a blood pressure, specifically an anti-hypertensive agent derived from a wheat protein, which has little or no inhibitory activity on angiotensin transferase and has an excellent anti-hypertensive effect. [MEANS FOR SOLVING PROBLEMS] An anti-hypertensive composition comprising, as an active ingredient, a water-soluble component produced by removing insoluble components from a proteolytic digestion product of a wheat protein, wherein the proteolytic digestion product is an acidic protease hydrolysate of a wheat protein or a neutral or alkaline protease hydrolysate of the acidic protease hydrolysate.
A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
[PROBLEMS] To provide a drug which has a selective β3 receptor activating effect and is useful in preventing or treating increased urinary frequency and urinary incontinence. [MEANS FOR SOLVING PROBLEMS] It is disclosed that 6-[2-(R)-[(2-[(R)-(3-chlorophenyl)-2-hydroxyethyl)amino]propyl]-2,3-dihydro-1,4-benzodioxy-2-(R)-carboxylic acid or a pharmacologically acceptable salt thereof is efficacious in preventing and treating increased urinary frequency and urinary incontinence, in particular, increased urinary frequency and urinary incontinence caused by hyperactive bladder.
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61P 13/02 - Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
A61P 13/10 - Drugs for disorders of the urinary system of the bladder
C07D 319/20 - 1,4-DioxanesHydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
The invention provides coenzyme Q10-containing compositions which are free from synthetic emulsifiers such as glycerol fatty acid esters, polyglycerol fatty acid esters, organic acid monoglycerides or sucrose fatty acid esters and which contain coenzyme Q10 at high proportion and are excellent in the stability of coenzyme Q10 and the bioavailability thereof. Coenzyme Q10-containing liquid compositions are obtained by dispersing and emulsifying coenzyme Q10 in an aqueous fluid containing a water-soluble substance composed of starch octenylsuccinate and dextrin and sorbitol and/or propylene glycol. Further, coenzyme Q10-containing solid compositions are obtained by drying the liquid compositions, if necessary, together with a carrier.
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
patents
